NCT02335424View on ClinicalTrials.gov

Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)

PHASE2CompletedINTERVENTIONAL

Enrollment

374

Participants

Timeline

Start Date

February 24, 2015

Primary Completion Date

June 19, 2018

Study Completion Date

February 18, 2022

Conditions

Urothelial Cancer

Interventions

BIOLOGICAL

pembrolizumab

IV infusion

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02335424 - Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052) | Biotech Hunter | Biotech Hunter